Discussions are underway in and outside the pharmaceutical industry to explore a new NHI price revision method for listed medicines that could replace the current rules based on market prices. Parties like the Study Group on Drug Pricing and Distribution…
ORGANIZATION
Citizen’s Group Opposes Emergency Approval for Shionogi’s COVID Pill
Medwatcher Japan, a citizen’s drug damage watchdog, issued a statement on June 20 opposing the proposed application of the newly introduced emergency approval system to Shionogi’s COVID-19 pill ensitrelvir, saying that the medicine does not meet the “presumed efficacy” criteria.…
To read the full story
Related Article
- Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
- Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
June 23, 2022
- Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
ORGANIZATION
- 3 Cell & Gene Therapies Make Up More than Half of Top 100 Bills in FY2021: Payer
September 22, 2022
- Sales Reps in Japan Decrease for 8 Years Straight as Voluntary Redundancy Weighs: FY2021 Report
September 21, 2022
- Shionogi’s COVID Pill Might Not Be Applicable for Emergency Approval: JPMA Exec
September 16, 2022
- JPMA Managing Director Tanaka to Retire, Ex-Chugai Official to Take Over
September 16, 2022
- JPMA to Present Proposal on Value-Based Drug Pricing at Upcoming Panel Hearing
September 16, 2022
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…